A London-based firm investing in venture capital and public equities in life sciences, focused on advanced therapies addressing high unmet medical and social needs.

4BIO Capital

4BIO Capital is an international venture capital firm focused solely on the advanced therapies sector. 

4BIO’s objective is to invest in, support, and grow early stage companies developing treatments in areas of high unmet medical need, with the ultimate goal of ensuring access to these potentially curative therapies for all patients. Specifically, it looks for viable, high-quality opportunities in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome.

The 4BIO team comprises leading advanced therapy scientists and experienced life science investors who have collectively published over 250 scientific articles in prestigious academic journals including Nature, The Lancet, Cell, and the New England Journal of Medicine. 4BIO has both an unrivalled network within the advanced therapy sector and a unique understanding of the criteria that define a successful investment opportunity in this space.

For more information, please visit www.4biocapital.com


Congratulations to our portfolio company Vianautis on having appointed Steven Altschuler M.D. as Chairman.
 
Dr Altschuler is a renowned biotech company founder, director and board leader with proven experience in successfully leading and supporting companies focused on advanced therapies and drug delivery systems including Spark Therapeutics, Inc. (acquired by Roche in 2019 for $4.8 billion), Orchard Therapeutics (a 4BIO Capital portfolio company acquired by Kyowa Kirin Co., Ltd. in 2024 for $477.6 million), Lexeo Therapeutics and 89bio.

#AdvancedTherapies #Nanomedicines #DrugDelivery #VC #Chairman #Appointment

We are thrilled to announce that our portfolio company, Hornet Therapeutics, has emerged from stealth with the publication of significant new data published in the prestigious journal, Science Magazine.

The published data demonstrate the first ever small molecule drug, HTX-201, with the potential for treating Epstein-Barr Virus driven (EBV) diseases.

HTX-201 was exclusively in-licensed from Kyowa Kirin Co., Ltd. and Hornet now looks forward to progressing at speed into proof-of-concept trials in solid organ transplant populations. 

Read the full press release: https://lnkd.in/eChcme7k

Read the publication in Science: https://lnkd.in/gtGHPXgs

#publication #4BIO #AdvancedTherapies #CompanyLaunch

We want to thank all our partners and our portfolio companies Araris Biotech AG, Ascend  , Carisma Therapeutics, Code Biotherapeutics, Entact Bio, Hornet Therapeutics, LUCA Science Inc., Ray Therapeutics, Inc. and SparingVision for joining us at our 2023 AGM last week where we were able to provide an update on the fund’s progress as well as discuss industry trends including environmental sustainability and what’s next in the advanced therapies space.

Special mention goes to Rahul Parekh of 2150 and Patient Advocate Tamar Bresge for providing their valuable insights.

#VC #AdvancedTherapies #4BIOAGM #AGM #Biotech

We were privileged to host Masami Sakoi, the Vice-Minister of Health and Tadayuki Mizutani, Director of the Policy Planning Division for the Pharmaceutical Industry of Japan and delegates from Japan’s Ministry of Health, Labour and Welfare at our offices in London.
 
Discussions revolved around the value proposition of incubators and accelerators in the life sciences field, as well as the mechanisms through which early-stage ventures interact and collaborate with accelerators. 
The meeting served as a valuable platform for knowledge sharing and collaboration between 4BIO Capital and representatives from Japan, reinforcing the importance of international partnerships in advancing the global life sciences landscape.
 
#AdvancedTherapies #DrugDelivery #VC #collaboration

It was a busy day at Bio€quity Europe 2024 here in San Sabastián, meeting other attendees from across the industry and our Managing Partner, Dmitry 'Dima' Kuzmin participating in the ‘Scaling up Europe’s academic engine in cell and gene therapy’ R&D showcase.

#AdvancedTherapies #GeneTherapy #CellTherapy #VC #showcase #BioEquity #Conference BioCentury Inc. EBD Group

Join our Managing Partner, Andrew Kozlov, tomorrow as he participates in the ‘How to Strengthen the Vital Link to Your Investors in Uncertain Times’ panel at the Swiss Biotech Day 2024 in Basel alongside Alexandra Wollersheim, Partner, Transaction Advisory Services, Alira Health, Ajla Hrle, Head of Life Sciences, ATHOS KG and Sarah Holland, Chief Business Officer, Cureteq AG - a Partex Company.

This panel will focus on practical solutions to restore the vital link between investors and innovators, recognizing their mutual dependence for value creation.

We hope to see you there!

https://lnkd.in/gBn4ZUd

#AdvancedTherapies #GeneTherapy #CellTherapy #VC #PanelDiscussion #SwissBiotech #Conference

Metric
Company Name	4
Symbol
MSH ID	COM:4BIOCAPITAL
Market	PRIVATE
Sector	Financial Services & Finance
Industry	Venture Capital and Investment
Country	GB
Stage
Employee Count	17
Website	4biocapital.com
LinkedIn	4bio-capital
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	1.70K
Web Traffic Growth	2.56
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:4BIOCAPITAL

4BIO Capital

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue